8 Inhibitors in congenital haemophilia

This publication has 27 references indexed in Scilit:

• Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large‐scale North American survey
  Haemophilia, 1996
• Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII
  American Journal of Hematology, 1994
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
  The Lancet, 1992
• Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor
  American Journal of Hematology, 1989
• Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIII
  New England Journal of Medicine, 1988
• Factor VIII Inhibitors
  Annals of the New York Academy of Sciences, 1987
• Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
  Journal of Clinical Investigation, 1983
• The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIII
  New England Journal of Medicine, 1981
• Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acid
  The Journal of Pediatrics, 1981
• Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII
  New England Journal of Medicine, 1980